VIRIDIAN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.88 USD | +1.42% |
|
-11.78% | -40.86% |
| Sales 2024 * | 307K 25.6M | Sales 2025 * | 3.11M 259M | Capitalization | 822M 68.54B |
|---|---|---|---|---|---|
| Net income 2024 * | -266M -22.18B | Net income 2025 * | -293M -24.43B | EV / Sales 2024 * | 1,315 x |
| Net cash position 2024 * | 418M 34.87B | Net cash position 2025 * | 587M 48.95B | EV / Sales 2025 * | 75.6 x |
| P/E ratio 2024 * |
-2.93
x | P/E ratio 2025 * |
-2.96
x | Employees | 94 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on Viridian Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +1.42% | ||
| 1 week | -11.78% | ||
| Current month | -26.44% | ||
| 1 month | -25.85% | ||
| 3 months | -35.24% | ||
| 6 months | +1.66% | ||
| Current year | -40.86% |
1 week
12.20
15.01
1 month
12.2017.93
Current year
12.2024.18
1 year
10.9328.99
3 years
9.4739.00
5 years
4.6747.40
10 years
4.67270.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 30/23/30 | |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 01/23/01 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/23/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 03/18/03 |
Tomas Kiselak
CHM | Chairman | 38 | 28/20/28 |
| Chief Executive Officer | 53 | 30/23/30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.06% | 237 M€ | +2.89% | - | |
| 0.02% | 2 M€ | -.--% | ||
| 0.01% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 12.88 | +1.42% | 538,173 |
| 25/24/25 | 12.7 | -2.53% | 958,729 |
| 24/24/24 | 13.03 | -8.56% | 771,185 |
| 23/24/23 | 14.25 | -0.35% | 538,427 |
| 22/24/22 | 14.3 | -2.05% | 812,430 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
12.88
USD
Average target price
39.36
USD
Spread / Average Target
+205.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.86% | 822M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- VRDN Stock
